Irritable bowel syndrome. Irritable bowel syndrome
Conditions
Interventions
Intervention 1: Intervention group 1: Daily 10-20 milligram Escitalopram manufactured in Sobhan Pharmaceutical Company for 8 weeks. Intervention 2: Intervention group 2: Daily 75-375 milligram Venlafa
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The Presence of ROME-III Diagnostic Criteria for Diagnosis of Irritable Bowel Syndrome To Provide the Informed Consent Form of the Patient for Participation in the Study
Exclusion criteria
Exclusion criteria: Age under 18 years Allergy to Escitalopram, Venlafaxine or Buspirone The presence of warning signs such as chronic fever, weight loss, gastrointestinal bleeding Pregnancy and breast feeding Use of any drug that can affect the bowel function (such as laxatives, anti-diarrhea, antibiotics and probiotics) within one month before entering the study Known cases of lactose intolerance Severe physical illnesses, mental retardation, dementia, psychosis, and the existence of serious suicidal ideation and substance dependence that affects patients' compliance with the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Irritable bowel syndrome symptoms. Timepoint: Baseline assessment and at the end of the eighth week of intervention. Method of measurement: According to ROME-III diagnostic criteria.;Patient´s quality of life. Timepoint: Baseline assessment and at the end of the eighth week of intervention. Method of measurement: According to the quality of life questionnaire IBS_QOL. | — |
Secondary
| Measure | Time frame |
|---|---|
| The drug side effects. Timepoint: At the fourth and eighth weeks of the intervention. Method of measurement: Visit of the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSussan Moudi, MD
Babol University of Medical Sciences
Outcome results
None listed